- Home
- GDL vs ALLK Comparison
GDL vs ALLK Comparison
Compare GDL & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDL
- ALLK
- Stock Information
- Founded
- GDL 2006
- ALLK 2012
- Country
- GDL United States
- ALLK United States
- Employees
- GDL N/A
- ALLK N/A
- Industry
- GDL Investment Managers
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- GDL Finance
- ALLK Health Care
- Exchange
- GDL Nasdaq
- ALLK Nasdaq
- Market Cap
- GDL 94.9M
- ALLK 101.0M
- IPO Year
- GDL N/A
- ALLK 2018
- Fundamental
- Price
- GDL $8.15
- ALLK $0.86
- Analyst Decision
- GDL
- ALLK Hold
- Analyst Count
- GDL 0
- ALLK 4
- Target Price
- GDL N/A
- ALLK $1.67
- AVG Volume (30 Days)
- GDL 11.2K
- ALLK 827.7K
- Earning Date
- GDL 01-01-0001
- ALLK 03-13-2025
- Dividend Yield
- GDL 6.02%
- ALLK N/A
- EPS Growth
- GDL N/A
- ALLK N/A
- EPS
- GDL N/A
- ALLK N/A
- Revenue
- GDL N/A
- ALLK N/A
- Revenue This Year
- GDL N/A
- ALLK N/A
- Revenue Next Year
- GDL N/A
- ALLK N/A
- P/E Ratio
- GDL N/A
- ALLK N/A
- Revenue Growth
- GDL N/A
- ALLK N/A
- 52 Week Low
- GDL $7.65
- ALLK $0.54
- 52 Week High
- GDL $8.13
- ALLK $1.69
- Technical
- Relative Strength Index (RSI)
- GDL 59.30
- ALLK 35.16
- Support Level
- GDL $8.12
- ALLK $0.81
- Resistance Level
- GDL $8.17
- ALLK $1.00
- Average True Range (ATR)
- GDL 0.06
- ALLK 0.13
- MACD
- GDL 0.01
- ALLK -0.03
- Stochastic Oscillator
- GDL 89.47
- ALLK 8.43
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.